PRL-8-53

Overview

PRL-8-53 is a non-peptide small-molecule aminoalkyl benzoic acid ester (methyl benzoate derivative), supplied as the hydrochloride salt. Originally characterized in 1974 animal studies as a spasmolytic and CNS-active agent, it has never been approved by any regulatory agency and is sold only as a research chemical. Exactly one published human trial exists—a 1978 double-blind study on verbal learning and retention—with no independent replication or modern safety data.

Mechanism of Action

No validated mechanism of action has been established in the peer-reviewed literature. The original 1974 pharmacology paper characterizes the compound only as a spasmolytic and CNS-active agent based on animal testing, with indexed study areas including avoidance learning, conditioning, memory, and interaction with apomorphine and methamphetamine, but no receptor-binding, enzyme-inhibition, or target-identification study for PRL-8-53 was found in PubMed or PubChem BioAssay data. Widely circulated claims on nootropic vendor sites regarding specific neurotransmitter effects or ion-channel subtypes are not supported by any primary source and are excluded as unverified marketing content.

Research Summary

Exactly one published human study was located: a 1978 double-blind trial (Hansl & Mead, <em>Psychopharmacology</em>, PMID 418433) using the serial anticipation method to test oral PRL-8-53 on verbal learning acquisition and retention, with follow-up on visual reaction time and motor control; the study reported statistically significant retention improvement (most P<0.01) and no significant reaction-time or motor effects, but sample size and exact dose are not stated in the available abstract. No further human trials were found, and no ClinicalTrials.gov entries exist. Preclinical work is limited to the 1974 Hansl paper (PMID 4824605) in dogs and rats, indexed for avoidance learning, conditioning, memory, and pharmacological interaction with apomorphine and methamphetamine, though full quantitative findings could not be verified because no abstract text is available.

Vendors selling PRL-8-53

Scored vendors carrying PRL-8-53, ranked by trust grade. Grades are computed from indexed Certificates of Analysis. Full $/mg pricing is on the comparison page.

Reported Side Effects

• No modern toxicology or long-term safety studies published
• No drug-interaction or dose-ranging data available
• Not evaluated by FDA, EMA, or any regulatory body
• Single 1978 trial reported no significant motor or reaction-time changes
• Distributed only as research chemical, not approved for human use

Compare PRL-8-53 with Others

Research References

• PRL-8-53: enhanced learning and subsequent retention in humans as a result of low oral doses of new psychotropic agent. 1978. PMID 418433.
• A novel spasmolytic and CNS active agent: 3-(2-benzylmethylaminoethyl) benzoic acid methyl ester hydrochloride. 1974. PMID 4824605.
• Prl-8-53, PubChem Compound Summary for CID 70700868.

Frequently asked questions

Has PRL-8-53 been independently lab-tested?

Disclosed Labs has collected 3 Certificates of Analysis (COA) for PRL-8-53 from 2 independent testing labs. 1 vendor has submitted material for testing. Products average 96.8% tested purity across the corpus. Full testing data is available at https://www.disclosedlabs.com/peptides/prl-8-53/testing.

What is the average purity of PRL-8-53 on the market?

Based on 3 COAs analyzed by Disclosed Labs, PRL-8-53 products average 96.8% (±1.1%) tested purity. Individual vendor results vary; see per-vendor COA data at https://www.disclosedlabs.com/peptides/prl-8-53/coas.

Where can researchers source PRL-8-53?

1 vendor with Disclosed Labs trust grades currently list PRL-8-53, including Kimera Chems. Compare live prices and lab-verified COAs at https://www.disclosedlabs.com/prices/prl-8-53.

How does PRL-8-53 work?

No validated mechanism of action has been established in the peer-reviewed literature. The original 1974 pharmacology paper characterizes the compound only as a spasmolytic and CNS-active agent based on animal testing, with indexed study areas including avoidance learning, conditioning, memory, and interaction with apomorphine and methamphetamine, but no receptor-binding, enzyme-inhibition, or target-identification study for PRL-8-53 was found in PubMed or PubChem BioAssay data. Widely circulated claims on nootropic vendor sites regarding specific neurotransmitter effects or ion-channel subtypes are not supported by any primary source and are excluded as unverified marketing content.

What does the research say about PRL-8-53?

Exactly one published human study was located: a 1978 double-blind trial (Hansl & Mead, <em>Psychopharmacology</em>, PMID 418433) using the serial anticipation method to test oral PRL-8-53 on verbal learning acquisition and retention, with follow-up on visual reaction time and motor control; the study reported statistically significant retention improvement (most P<0.01) and no significant reaction-time or motor effects, but sample size and exact dose are not stated in the available abstract. No further human trials were found, and no ClinicalTrials.gov entries exist. Preclinical work is limited to the 1974 Hansl paper (PMID 4824605) in dogs and rats, indexed for avoidance learning, conditioning, memory, and pharmacological interaction with apomorphine and methamphetamine, though full quantitative findings could not be verified because no abstract text is available.